<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232932</url>
  </required_header>
  <id_info>
    <org_study_id>P120106</org_study_id>
    <nct_id>NCT02232932</nct_id>
  </id_info>
  <brief_title>Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma</brief_title>
  <acronym>TRANSPHIL</acronym>
  <official_title>Randomized Prospective Multicentric Study: Radio-chemotherapy and Liver Transplantation Versus Liver Resection to Treat Respectable Hilar Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, randomised, multicentre, comparative study in two parallel groups&#xD;
      comparing an interventional group with liver transplantation preceded by neoadjuvant&#xD;
      radio-chemotherapy and a control group receiving conventional liver and bile duct resection.&#xD;
&#xD;
      The primary endpoint will be overall survival at 5 years in the intent-to-treat population.&#xD;
      The secondary endpoint will be recurrence-free survival at 3 years evaluated by CT-scan and&#xD;
      tumoral markers (Carcinoembryonic antigen (CAE) and cancer antigen (CA19.9)) in the&#xD;
      intent-to-treat population.&#xD;
&#xD;
      The number of subjects necessary is 54 patients (27 x 2): this population will enable the&#xD;
      demonstration of a significant difference is 5-year survival rates between the transplanted&#xD;
      group and the resected group with a power of 80% and a first-species risk of 5%, under the&#xD;
      hypothesis that these survival rates are 70% in the transplanted group and 30% in the&#xD;
      resected group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol will comprise a phase 1 during which the potential eligibility of patients&#xD;
      (presenting with a resectable Klatskin - Excepted Type 1of Bismuth) will be assessed, based&#xD;
      on clinical, biological and morphological data. After phases 1, the eligibility of the&#xD;
      patient will be confirmed or not. In the context of the study, phase 2 will include the&#xD;
      collection of blood samples as well as positon emission tomography (PET)-scan and upper&#xD;
      endoscopic ultrasound (EUS) in order to rule out any obvious lymph node metastases. A short&#xD;
      exploratory laparoscopy will also be performed in phase 2 to eliminate infra-clinic&#xD;
      subcapsular liver metastases and peritoneal carcinomatosis. The randomization process will&#xD;
      take place at the end of the phase 2, patients will be assigned into the transplantation arm&#xD;
      (OLT) or the resection arm (RSX). During phase 3, patient will receive nutritional support&#xD;
      and, if not done previously, a biliary drainage will be placed endoscopically. In the RSX arm&#xD;
      (phase 3A), patients will undergo radical resection of the tumor (refer below technical&#xD;
      details). Preoperative portal vein embolization may be necessary at this stage depending on&#xD;
      the expected remnant liver volume, assessed by CT-scan volumetry. In the OLT arm (phase 3A),&#xD;
      patients will receive neoadjuvant radiochemotherapy (External - 50 grays) following by liver&#xD;
      transplantation (phase 4B). Before the fifth week after completion of radiochemotherapy, a&#xD;
      staging laparotomy with local lymphadenectomy will be performed and patients will be put on&#xD;
      the national waiting list in the absence of extra-hepatic disease, especially peritoneal&#xD;
      seeding and lymph nodes involvement. A score exception will allowed a liver transplantation&#xD;
      in the 3 months after staging laparotomy. During phase 5 the patient will be monitored&#xD;
      postoperatively at the clinical, biological and morphological levels for 3 months. During&#xD;
      phase 6, the patient will be followed clinically, biologically and morphologically for 5&#xD;
      years in order to detect any recurrence and in the context of standard clinical care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 5 years</time_frame>
    <description>To demonstrate the superiority, in terms of 5-year survival, of liver transplantation (TH) preceded by neoadjuvant chemoradiotherapy on the radical resection of Klatskin tumors considered resectable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>At 3 years</time_frame>
    <description>3-year recurrence-free survival assessed by CT and markers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>CAPECITABINE-Radiotherapy -Liver Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RESECTION</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liver resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CAPECITABINE-Radiotherapy -Liver Transplantation</intervention_name>
    <description>CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation</description>
    <arm_group_label>CAPECITABINE-Radiotherapy -Liver Transplantation</arm_group_label>
    <other_name>Neoadjuvant Radio-Chemotherapy and Liver Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RESECTION</intervention_name>
    <description>Intent-to-treat R0 liver resection</description>
    <arm_group_label>RESECTION</arm_group_label>
    <other_name>Liver Resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (male or female) aged from 18 to 68 year-old, French&#xD;
&#xD;
          -  Hilar cholangiocarcinoma histologically proved and/or highly suspected on hilar&#xD;
             stenosis with mass syndrome from 0.1 cm to 3 cm&#xD;
&#xD;
          -  Hilar cholangiocarcinoma type 2, type 3A, type 3B, type 4&#xD;
&#xD;
          -  Patients considered as resectable (R0 resection) by liver resection including segment&#xD;
             1 and biliary confluence with or without vascular resection&#xD;
&#xD;
          -  Patient potentially transplantable&#xD;
&#xD;
          -  Patient affiliated to French Health Insurance&#xD;
&#xD;
          -  Patient who had sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Women of childbearing potential without an effective contraception method&#xD;
&#xD;
          -  Radiotherapy contraindication&#xD;
&#xD;
          -  Positive dosage of ImmunoglobulinsG4 (IgG4)&#xD;
&#xD;
          -  dihydro-pyrimidine-dehydrogenase (DPD) total deficit&#xD;
&#xD;
          -  Personal history of cancer in the last 5 five years (exclusion basocellular cellular&#xD;
             carcinoma)&#xD;
&#xD;
          -  Personal history of fluoropyrimidine hypersensibility&#xD;
&#xD;
          -  Personal history of capecitabine hypersensibility&#xD;
&#xD;
          -  Personal history of dihydro-pyrimidine-dehydrogenase deficit&#xD;
&#xD;
          -  Polynuclear neutrophil &lt; 1500 / ml&#xD;
&#xD;
          -  Platelet rate &lt; 100 000 / ml&#xD;
&#xD;
          -  Severe leucopenia &lt; 2000 / ml&#xD;
&#xD;
          -  Severe liver failure (Factor V &lt; 50%)&#xD;
&#xD;
          -  Severe renal failure (Creatin clearance &lt; 30 ml/min)&#xD;
&#xD;
          -  Treatment by Sorivudine or its analogue as Brivudine&#xD;
&#xD;
          -  Non controled diabetes mellitus and/or others severe co-morbidities (renal failure,&#xD;
             severe and instable coronaropathy, severe risk factor of stroke, body mass index&#xD;
             superior to 35)&#xD;
&#xD;
          -  Proved histological cirrhosis&#xD;
&#xD;
          -  Sclerosing cholangitis&#xD;
&#xD;
          -  Intra and/or extra-hepatic metastases&#xD;
&#xD;
          -  Hypereosinophilia and/or wirsung dilatation and/or mass of the pancreas head&#xD;
&#xD;
          -  Hilar mass superior to 3 cm&#xD;
&#xD;
          -  Duodenal invasion&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric VIBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire, Villejuif, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire</name>
      <address>
        <city>Villejuif</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hilar cholangiocarcinoma</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

